Field Guide · Deconstructed
Peptides are tiny protein fragments — short signaling molecules the body already uses to tell the immune system, the gut, and damaged tissue what to do. A handful of them have become quiet workhorses in the chronic-illness world: to rebuild a depleted immune system, heal a leaky gut, and calm the inflammation that mold and infection leave behind. Here are the facts: which peptides are actually used, what the evidence really says for each, the one risk that matters most — where you get them — how they’re dosed, and how to source them safely instead of from a gray-market vial.
I walked this part of the labyrinth myself — knocked on the doors, read the research, and came back with the map. You don’t have to find the way out alone.
Peptides are short chains of amino acids — smaller than proteins, bigger than a single building block — that act as signaling molecules. Your body makes thousands of them; insulin is one, the hormones that govern hunger are others. The peptides used therapeutically here are mostly copies of signals the body already sends: a message that says “mature more T-cells,” “repair this gut lining,” “dial down this inflammation,” or “kill this microbe.”
That’s why they’re interesting for a PANS, Lyme, or mold/CIRS family. The chronic-illness picture is rarely just one infection — it’s an immune system that’s exhausted or dysregulated, a gut lining that’s leaky, and tissue that won’t heal. Peptides are some of the few tools that try to send the body a corrective signal rather than kill a bug. That’s the appeal — and, as below, the evidence is very uneven from one peptide to the next, so they have to be judged one at a time.
The mental model: most of this map is about killing something — bugs, biofilm, mold. Most peptides are the opposite move: sending a signal to rebuild, repair, or regulate. A couple (LL-37, KPV) do help kill or calm microbes, but the headline peptides here belong in the “repair the system” column, not the “kill the infection” column.
There are many peptides marketed; only a handful show up repeatedly in serious PANS/Lyme/mold practice. The single most important thing to understand is that the evidence is wildly different from one to the next — one has decades of human trials, several have almost none. Read the evidence column, not the hype.
| Peptide | What it’s for | Evidence — honest |
|---|---|---|
| Thymosin alpha-1 TA1 / thymalfasin / Zadaxin | Immune reconstitution & modulation — matures T-cells, lifts CD4 counts, tunes an exhausted/dysregulated immune system. The go-to for chronic / persistent infection. | The strongest of the group — real human research. Approved in 35+ countries; FDA orphan-drug status (thymalfasin) for hepatitis B, melanoma, DiGeorge; trials in HIV, hepatitis C, sepsis, COVID. Decades of safety data. |
| BPC-157 “body protection compound” | Gut + tissue/connective healing — ulcers, leaky gut, IBD models, tendon/ligament repair. The popular “gut-repair” peptide. | Largely preclinical. 100+ animal studies, remarkably consistent for GI repair — but a 2025 review of 544 papers found essentially no completed human efficacy trials. Promising, unproven in people. |
| Thymosin beta-4 / TB-500 | Tissue repair & cell migration — wound healing, muscle/tendon, some anti-microbial/biofilm signal. | Animal-level for TB-500. The promising Phase-2 human data used full-length thymosin beta-4, not the TB-500 fragment sold online. Treat as preclinical. |
| LL-37 cathelicidin | Antimicrobial peptide — the body’s own broad-spectrum defense against bacteria, fungi, viruses; anti-biofilm; recruits repair. | Strong lab + correlative human data, no interventional trials. Real mechanism, real anti-biofilm activity — but it has not been proven as a treatment in controlled human studies. |
| KPV fragment of alpha-MSH | Anti-inflammatory — calms gut and systemic inflammation, mast-cell-adjacent; used for GI inflammation + MCAS-type pictures. | Mostly preclinical / mechanistic. Plausible mechanism (alpha-MSH biology), limited human trial evidence. Low-risk reputation, weak proof. |
| VIP vasoactive intestinal peptide (nasal) | Mold / CIRS recovery — the final step in Shoemaker’s biotoxin protocol; restores immune/hormone regulation after biotoxin exposure is removed. | Shoemaker case-series + small published studies (incl. grey-matter volume work). Used in 10,000+ CIRS patients with a strong safety record — but evidence is largely from one research group. |
| Cerebrolysin & others | Neuro / brain support — Cerebrolysin (neurotrophic), Selank/Semax (anxiety, focus). Of interest where there’s a neuroinflammatory/regression picture. | Mixed — mostly studied abroad. Cerebrolysin has trials in stroke/dementia (quality debated); Selank/Semax are Russian-approved with limited Western data. The most speculative corner. |
The Plan B read for a kid: if peptides are on your table at all, the two with the clearest rationale are TA1 for immune support (because it has real human research behind it) and, in a mold/CIRS picture, VIP nasal as the last step after exposure is removed (per Shoemaker’s sequence). BPC-157 for gut repair is reasonable to consider but should be labeled honestly as preclinical. Everything else is more experimental — under a prescriber, not on your own. TA1 comprehensive review, 2020 · Shoemaker VIP, 2013
This decision tree is only for a family working with a prescriber. Start at the top and follow your situation; each step is backed by the evidence on this page. Tap to open.
A gray-market “research chemical” vial → STOP. This is the single biggest risk on the page — unknown purity, possible contamination.
A knowledgeable prescriber + reputable compounding pharmacy → you may continue ↓
Exhausted / dysregulated immune system + chronic infection → TA1 (the most-researched).
Leaky gut / tissue repair → BPC-157 (label it preclinical).
Mold / CIRS, exposure already removed → VIP nasal (Shoemaker’s last step). Match the peptide to the problem — don’t stack them all.
If there’s a mold/CIRS picture, VIP is the LAST step — only after exposure is removed and drainage is open. Don’t start it early. Jump to dosing.
Lowest reasonable dose, with a provider, one new thing at a time so you can tell what’s working. Most are small subcutaneous injections (VIP is nasal). Jump to dosing.
Peptides clear the body fast, so stopping is the main lever. But before you blame the peptide, suspect the vial — the most common cause of a bad reaction is unknown-quality product. Jump to the reverse / safeguard.
This is a lot to weigh — and you don’t have to weigh it alone. Minta has all of this synthesized. She’ll look at your child, tell you honestly whether peptides even belong on your table, and if they do, help you pick the right one, find a real prescriber + pharmacy, and plan the start-low dose — then walk it with you. Let Minta do this with you →
This is the section that matters most, and it’s the one nobody selling peptides wants to dwell on. The peptides themselves are mostly low-toxicity. The danger is almost entirely about where the vial came from.
Most peptides sold online are marketed as “research chemicals — not for human consumption.” That label is a legal dodge: it exempts the seller from FDA oversight, pharmaceutical manufacturing standards, and any requirement to prove purity, potency, or sterility.
In September 2023 the FDA placed BPC-157 (and several other peptides) on its “Category 2” bulk-substances list — substances flagged for significant safety questions, effectively blocking compounding pharmacies from using them. The agency cited possible immune reactions, manufacturing impurities, and a lack of human safety data. (In April 2026 BPC-157 was removed from that Category 2 list — but that is not FDA approval; it remains an unapproved, investigational compound.) The practical takeaway hasn’t changed: availability and quality are genuinely unsettled, so the source is everything. FDA interim 503A bulk-substances policy
A knowledgeable prescriber + a reputable compounding pharmacy — not a gray-market vial. This matters most for TA1 (the one with the real human track record) and VIP (which a CIRS-literate clinician compounds and sequences). A real prescriber sources from a pharmacy that tests for sterility and endotoxins, sets a weight-appropriate dose, and watches the child. That sourcing decision is the actual safety story of peptides. TA1 review · Shoemaker on compounded VIP
Read this as “what’s typically used in the real world,” not a prescription. There is no FDA-approved pediatric peptide protocol for any of this. The universal rule holds harder here than anywhere: start low, go slow, one new thing at a time, with a prescriber, from a reputable compounding pharmacy. Most peptides are tiny subcutaneous injections; VIP is the exception — it’s nasal.
| Peptide | Route | How it’s typically used |
|---|---|---|
| TA1 | Subcutaneous | Small subq injections (commonly a few times weekly), adjusted by the prescriber. The one with established adult dosing literature — pediatric use is off-label and weight-based. |
| BPC-157 | Subcutaneous (or oral) | Low subq doses (or oral capsules from a compounding pharmacy) for a defined course. Start low — preclinical, no validated human dose. |
| TB-500 | Subcutaneous | Periodic subq dosing for a tissue-repair window. Experimental — provider-directed only. |
| LL-37 / KPV | Subcutaneous / topical / oral | Provider-specified; KPV often oral for gut inflammation. Niche, low-dose, under guidance. |
| VIP | Nasal | Compounded nasal spray, ~50 mcg/spray, several sprays daily in Shoemaker’s protocol — but only as the last step, after exposure is removed and prerequisites are met. |
The pattern to notice: these are small, signal-level doses, not big drug loads — which is part of why the molecules themselves are relatively low-toxicity. The dose is not where the risk lives; the source is. A perfectly “correct” dose of a contaminated vial is still dangerous. VIP dosing, Shoemaker 2013
This is the part that matters most. Before you start, you answer one question out loud: “If this goes wrong, exactly how do I make it stop?” With peptides the honest answer is unusual — there’s no specific antidote drug, because the main lever is simply stopping (peptides clear the body quickly), and the main risk isn’t the peptide at all — it’s an unknown-quality product. So the real safeguard is upstream, in the sourcing.
| Situation | What you do |
|---|---|
| Reacting to the peptide itself | Stop dosing. Most peptides are cleared fast, so the exposure ends quickly once you stop — there is no dramatic reversal agent because there’s usually no lingering depot. |
| Signs of contamination (fever, chills, injection-site infection, a sepsis-like reaction) | This is a medical emergency — seek care. It points at endotoxin / contamination in the vial, not a normal peptide effect. This is the failure mode the gray market produces. |
| Mold/CIRS, started VIP too early | Stop the VIP, go back and finish exposure removal + drainage first — VIP is the last step for a reason; running it early can backfire. |
FDA Interim Policy on Compounding Using Bulk Drug Substances (503A) — the regulatory backdrop for why pharmacy sourcing matters.
The single biggest mistake families make is treating “peptides” as one thing. They aren’t. Here’s the straight version, strongest to weakest.
Thymosin alpha-1 is the outlier with genuine clinical evidence. It’s approved in 35+ countries and carries FDA orphan-drug status (as thymalfasin/Zadaxin) for hepatitis B, melanoma, and DiGeorge anomaly. It has been studied in hepatitis C, HIV, sepsis, and COVID, with a long safety record. That’s why it’s the peptide most defensible for immune support in a chronic/persistent-infection picture. TA1 comprehensive review, 2020
The honest label: one strong (TA1), several emerging, nothing studied specifically for PANS. No controlled trial has tested any of these for PANS. TA1 for immune support and VIP for CIRS are the most defensible; the rest are “reasonable to explore with a prescriber and eyes open,” not “this works.”
Credentials, polish, and how conventional an approach sounds tell you little about whether a practitioner will help your child — or harm them. What does: their behavior and their incentives. Watch those.
Peptides attract both careful clinicians and pure sales operations — and they can look alike. Don’t judge by the slick “regenerative” branding or the long peptide menu; judge the conduct and the incentives.
Peptides are signaling molecules — short messages to a stalled immune system, a leaky gut, or inflamed tissue — and a few have a real place on the “what hasn’t been tried” menu, as long as you judge them one at a time. TA1 is the standout with genuine human research (immune support for chronic infection); VIP nasal is the established last step of Shoemaker’s mold/CIRS protocol; BPC-157 is reasonable for gut repair but is largely preclinical — label it honestly; the rest are more experimental. The risk that actually matters is not the molecule — it’s the source. If peptides are on your table: go through a knowledgeable prescriber and a reputable compounding pharmacy, never a gray-market vial; start low, subcutaneous (VIP nasal); and remember the real safeguard is sourcing, because there’s no antidote for a contaminated injection. This is parent education, not medical advice — bring it to your team as questions, not instructions.
Plan B does not partner with drug companies or doctors, and we never endorse anyone whose healing isn’t verified by families. We show you the options and how to vet them yourself — and we’re building parent verification: look up a practitioner and see real family reviews before you trust them. Universal bad reviews? Skip.